Nanobiotix Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Nanobiotix de 36.5% y 21.9% respectivamente, mientras que el BPA crecerá en un 36.4% al año.

Información clave

36.5%

Tasa de crecimiento de los beneficios

36.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	10.9%
Tasa de crecimiento de los ingresos	21.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	15 Feb 2025

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%

Nov 28

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 29

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

May 14

Previsiones de crecimiento de beneficios e ingresos

ENXTPA:NANO - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2027	44	-14	N/A	7	4
12/31/2026	41	-29	-6	-16	7
12/31/2025	28	-47	-45	-47	8
12/31/2024	19	-51	-47	-43	8
6/30/2024	42	-33	-2	-1	N/A
3/31/2024	39	-37	-7	-7	N/A
12/31/2023	36	-40	-13	-12	N/A
9/30/2023	21	-49	-25	-25	N/A
6/30/2023	7	-59	-37	-37	N/A
3/31/2023	6	-58	-37	-37	N/A
12/31/2022	5	-57	-37	-37	N/A
9/30/2022	4	-50	-35	-35	N/A
6/30/2022	3	-43	-33	-32	N/A
3/31/2022	3	-45	-31	-31	N/A
12/31/2021	3	-47	-30	-30	N/A
9/30/2021	2	-45	-30	-30	N/A
6/30/2021	2	-43	-30	-30	N/A
3/31/2021	2	-39	-29	-29	N/A
12/31/2020	2	-34	-28	-28	N/A
9/30/2020	2	-41	-31	-30	N/A
6/30/2020	2	-48	-33	-33	N/A
3/31/2020	2	-49	-38	-37	N/A
12/31/2019	3	-51	-43	-41	N/A
9/30/2019	3	-46	-38	-37	N/A
6/30/2019	3	-42	-34	-33	N/A
3/31/2019	3	-36	-30	-30	N/A
12/31/2018	3	-30	-26	-26	N/A
9/30/2018	4	-28	-25	-24	N/A
6/30/2018	4	-27	-24	-22	N/A
3/31/2018	4	-26	N/A	-22	N/A
12/31/2017	4	-26	N/A	-21	N/A
9/30/2017	4	-25	N/A	-20	N/A
6/30/2017	4	-24	N/A	-19	N/A
3/31/2017	5	-23	N/A	-19	N/A
12/31/2016	5	-22	N/A	-18	N/A
9/30/2016	5	-21	N/A	-19	N/A
6/30/2016	5	-19	N/A	-20	N/A
3/31/2016	5	-18	N/A	-19	N/A
12/31/2015	4	-17	N/A	-17	N/A
9/30/2015	4	-15	N/A	-15	N/A
6/30/2015	3	-13	N/A	-12	N/A
3/31/2015	3	-11	N/A	-11	N/A
12/31/2014	3	-10	N/A	-9	N/A
9/30/2014	2	-9	N/A	-8	N/A
6/30/2014	2	-8	N/A	-8	N/A
3/31/2014	2	-8	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NANO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NANO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NANO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21.9% al año) de NANO crezcan más rápidamente que los del mercado French (5.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (21.9% al año) de NANO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NANO se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/02/16 15:52
Precio de las acciones al final del día	2025/02/14 00:00
Beneficios	2024/06/30
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Nanobiotix S.A. está cubierta por 16 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Mickael Chane-Du	Bryan Garnier & Co
Philippa Gardner	Edison Investment Research
Jonathan Miller	Evercore ISI

Nanobiotix Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 40%

Consensus revenue estimates increase by 16%, EPS downgraded

Forecast to breakeven in 2026

Consensus revenue estimates fall by 24%

Consensus revenue estimates increase by 26%

Consensus revenue estimates increase by 420%

Recent updates

Nanobiotix Announces First Patient Dosed in A New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients with Stage 3 Unresectable Non-Small Cell Lung Cancer

Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%

Consensus revenue estimates fall by 40%

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

New minor risk - Profitability

Forecast to breakeven in 2026

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Consensus revenue estimates fall by 24%

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Consensus revenue estimates increase by 26%

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Consensus revenue estimates increase by 420%

Price target increased by 23% to €19.03

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

Price target increased by 15% to €25.17

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Price target decreased to €21.90

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Price target decreased to €22.90

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Price target decreased to €23.18

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Price target increased to €29.67

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Consensus EPS estimates fall to -€1.29

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

New 90-day high: €17.20